多国COVID-19试验的审批延迟:COPCOV案例与治疗惰性风险
该案例研究以COPCOV试验为例,定量与定性分析学术研究者在大流行期间多国审批面临的手续障碍。研究者向76个国家申请审批,各国首次决定中位时间104天(IQR 42);有快速审查系统的国家决定更快(中位91天 vs 122天)。作者认为审批挑战源于保守的良好临床实践解读与国际指导不足,造成治疗惰性风险。
要点
- COPCOV试验在76个国家申请审批,各国首次决定中位时间104天(IQR 42)。
- 有快速审查系统的国家决定中位91天,无快速系统为122天。
- 约半数国家采用伦理与监管序贯审查,效率、灵活性与决策一致性问题导致延迟。
核心结论
- 试验审批挑战源于保守的良好临床实践解读与国际指导与领导不足,在公共卫生紧急事件中造成危险的「治疗惰性风险」。
- 治理改革应 twofold:改善国家对现有协调与风险结构的认知、支持与资助,并建立卫生紧急事件期间的全球临床研究框架。
研究设计与样本
- 采用COPCOV试验的扩展案例研究,定量与定性分析学术研究者在大流行期间多国审批面临的手续障碍。
- 测量从首次向各国伦理/监管机构提交COPCOV试验方案到首次批准的中位时间,并按伦理委员会与监管机构分解平均与中位审批时间。
- 数据提取自试验主文件中的官方文件、各国研究者记录及数千封利益相关者邮件。
- 对65名试验利益相关者进行半结构化访谈,并采用归纳主题分析识别审批障碍。
主要发现
- COPCOV研究者在76个国家申请审批,向22个地方/机构伦理委员会或机构审查委员会、19个多中心或国家伦理委员会及14个国家监管机构提交了初始方案。
- 各国首次决定(批准或拒绝)的中位时间为104天(IQR 42)。
- 约半数提交COPCOV方案的国家采用伦理与监管序贯审查系统,有快速审查系统的国家决定更快(中位91天 vs 122天)。
- 效率挑战包括伦理机构间意见重叠及伦理与监管机构角色重复。
- 灵活性不足源于对已上市药物现有风险框架认知不足、紧急审查中简化文件要求的机制少及监管灵活性与依赖机制利用不足。
临床怎么用
- 作者认为改革应 twofold,聚焦改善国家对现有协调与风险结构的认知、支持与资助,并建立卫生紧急事件期间的全球临床研究框架。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many multi-country COVID-19 clinical trials, including those for widely available repurposed drugs with strong safety profiles, were conceptualised quickly but were unable to influence clinical treatment guidelines. The Chloroquine/Hydroxychloroquine for the Prevention of COVID-19 (COPCOV) trial, a large multi-country clinical trial sponsored by the University of Oxford, sought to determine the efficacy of hydroxychloroquine and chloroquine as a prophylaxis for COVID-19 but faced approval delays and other bureaucratic challenges. Understanding the reasons for these delays will help to guide reform for future multi-country trials responding to health emergencies. METHODS: Using an extensive case study of the COPCOV trial, we aimed to quantitatively and qualitatively analyse the bureaucratic challenges facing academic researchers seeking trial approval across multiple countries during health emergencies. We measured the median time from first COPCOV trial protocol submission to an ethics/regulatory body in each country to first approval and disaggregated the average and median time for approval by ethics committees and regulatory bodies. These data are extracted from official documents in the Trial Master File, records from country investigators, and thousands of stakeholder emails. Additionally, we conducted semi-structured interviews with 65 trial stakeholders to identify barriers to approval, and we analysed these interviews using inductive thematic analysis. RESULTS: For the COPCOV trial, investigators sought approval in 76 countries and submitted initial protocols to 22 local/institutional ethics committees or institutional research boards, 19 multisite or national ethics committees, and 14 national regulatory authorities. The median time for the study to receive an initial decision (approval or rejection) in each country was 104 days (IQR 42). Approximately half of the countries to which the COPCOV protocol was submitted had sequential systems for ethics and regulatory review, and those with an expedited review system communicated faster decisions (median 91 days vs. 122 days). Issues with efficiency, flexibility, and decision-making coherence underpinned these approval delays. Efficiency challenges included overlap in comments between ethics bodies and duplicative ethics and regulatory body roles. Delays due to inflexibility resulted from under-awareness of existing risk-based frameworks for repurposed drugs, few mechanisms for streamlining documentation requirements during emergency review processes, and under-utilisation of regulatory agility and reliance mechanisms. Objectivity and coherence of decision-making by trial approval bodies were limited by a lack of stringent regulatory authority transparency and limited communication channels between trial stakeholders. CONCLUSIONS: Trial approval challenges are rooted in a combination of conservative good clinical practice interpretation and insufficient international guidance and leadership, which contribute to a dangerous 'risk of therapeutic inertia' in developing evidence during public health emergencies. Governance reforms to address these challenges should be twofold, focused on improving national awareness, buy-in, and financing for existing harmonisation and risk-based structures and establishing a global framework for clinical research during health emergencies. TRIAL REGISTRATION: ClinicalTrials.gov NCT04303507. Registered on 11 March 2020.
引用
- Winters J, Schilling WH. Approval delays in multi-country COVID-19 trials: the case of COPCOV and the risk of therapeutic inertia. Trials. 2025. PMID: 41402852. doi:10.1186/s13063-025-09300-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。